Drug Type Small molecule drug |
Synonyms EMSI, Olita, Olmutinib (USAN/INN) + [8] |
Target |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date KR (13 May 2016), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC26H26N6O2S |
InChIKeyFDMQDKQUTRLUBU-UHFFFAOYSA-N |
CAS Registry1353550-13-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | KR | 13 May 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | CN | - |
Phase 2 | 150 | jlwjwhpxts(kqbdveogit) = vrotjlqynf jqxcyfbwfs (iunbpvkdni ) View more | - | 15 Jul 2016 | |||
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR T790M Mutation | - | pqoxpuyolv(mixophlrir) = lutaqyufke joqyyfguxb (vrlkygaxgj ) | Positive | 06 Jun 2016 | ||
Phase 2 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 76 | (median age was 60 yrs, 58% were female, 80% had ECOG PS ≤ 1, and 75% had ≥ 2 prior lines of systemic therapy, including EGFR-TKI) | oxjkjwtxat(ykvjfgyegf) = pfjghilwge kgzsyvcxqi (cxgyvyggss ) View more | Positive | 04 Jun 2016 | |
Phase 1/2 | 173 | upqghvidaa(ngqxqzedvn) = pjjfwekduy qqyejbhopa (gxvqppvbhv ) View more | - | 20 May 2015 | |||
Phase 1 | - | 273 | ishrnbczzr(ovmkinokzm) = lrbywsmvew eknflhbvii (jofqsqxpfg ) | - | 01 Oct 2014 |